Leading CNS pharma and emerging biotechs are rapidly investing into digital technologies to support the transformation of neurological drug development through more objective, frequent, sensitive, and less invasive measures of movement, speech, and cognition. At the cusp of their implementation into translational and clinical studies, the field still needs to overcome the teething issues to achieve translatable, scalable, and accepted digital neurological biomarkers.
2023 was the time to secure new business and form connections with the top companies and new faces revolutionizing clinical assessments in neuroscience translational development.
Don’t miss your opportunity to join this positive audience of digital health experts looking to discover exciting new technologies and devices and clinical innovation leaders seeking novel solutions to modernize their neurological candidate pipelines.
CNS Pharma and Biotech Companies Seek:
Medical device and software providers for digital clinical assessments
Wearable technologies and sensors to facilitate sensitive, remote patient data collection
Early-stage patients to test efficacy in promising emerging drug candidates
Clinical CROs with expertise in digital health
Decentralized clinical trials specialists to facilitate efficient and engaged remote data collection
Novel digital biomarker technology to measure speech, cognition, movement, and sleep to monitor neurological disease progression
- Network with biopharma key opinion leaders and decision-makers at the forefront of neurological digital biomarker and endpoint development to forge new business opportunities
- Secure your company as an innovative field leader by presenting your product or service to an engaged audience of translational digital health experts
- Meet new and upcoming neuroscience companies currently in translational development, yet to select long-term commercial partners